Clinical Research Directory
Browse clinical research sites, groups, and studies.
Clinical Study on the Treatment of Systemic Sclerosis With UTAA91 Injection.
Sponsor: PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Summary
This clinical trial is designed as a single-arm, open-label, single-center investigator-initiated early-phase study, with the primary objective of evaluating the safety of UTAA91 injection in subjects with refractory moderate-to-severe active systemic sclerosis.
Official title: Clinical Study on the Treatment of Refractory Moderate-to-Severe Active Systemic Sclerosis With UTAA91 Injection
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
24
Start Date
2025-06
Completion Date
2040-01
Last Updated
2025-05-21
Healthy Volunteers
No
Conditions
Interventions
UTAA91 injection
CAR-modified gamma delta T cells
Locations (1)
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China